Compare EHI & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHI | CNTB |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.9M | 140.4M |
| IPO Year | 2003 | 2020 |
| Metric | EHI | CNTB |
|---|---|---|
| Price | $5.35 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.88 |
| AVG Volume (30 Days) | 136.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | $11,291.47 |
| Revenue Next Year | N/A | $74.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.27 | $0.85 |
| 52 Week High | $6.55 | $3.82 |
| Indicator | EHI | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 38.38 |
| Support Level | $5.35 | $0.85 |
| Resistance Level | $5.50 | $2.74 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 36.74 | 3.46 |
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.